canadian researchers are closing in on understanding the high prevalence of
leukemia
in down syndrome patients, paving the way for new therapies to eradicate the cancer of the blood and bone marrow before it has a chance to develop. their findings could be good news in the fight against pediatric leukemia in all children.
a study, conducted at the princess margaret cancer centre in toronto and
published in the journal science
, used a preclinical model to map out precisely how and where the disease originates during fetal development.
what is down syndrome?
down syndrome is a genetic disorder that occurs when an extra copy of chromosome 21 is produced by a random error during cell division in the early stages of human development. the disease is the most frequent genetic anomaly in canada, occurring in roughly 1 in every 781 babies born in the country,
according to the down syndrome association of toronto
. in addition to the physical traits and developmental delays associated with down syndrome, this extra chromosome contributes to a 150-fold increase in the risk of a myeloid leukemia diagnosis within the first five years of a newborn’s life.
researchers have long struggled to understand the exact blood cell type in which leukemia first forms, and which genetic changes make the cell preleukemic before it transforms into acute leukemia.
“a whole sequence of cellular events have already happened before a person is diagnosed with the disease,”
said john dick
, co-senior author of the study and a senior scientist at princess margaret. “you can’t tell at that point which sequence of events happened first, you just know that it has already happened.